Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent Deferred Tax AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascentage Pharma Group International (AAPG) Inventory (2023 - 2025)

Ascentage Pharma Group International posted quarterly Inventory of $4.0 million for Q4 2025, up 339.34% year-on-year from $918406.1 in Q4 2024, and up 236.52% on a QoQ basis from $1.2 million in Q2 2025.

Ascentage Pharma Group International (AAPG) has 3 years of Inventory data on file, last reported at $4.0 million in Q4 2025.

  • For the quarter ending Q4 2025, Inventory rose 339.34% year-over-year to $4.0 million; the trailing twelve-month figure through Dec 2025 stood at $4.0 million (up 339.34% YoY), and the FY2025 full-year result was $4.1 million, up 352.65% from the prior year.
  • Inventory for Q4 2025 stood at $4.0 million, up from $1.2 million in the prior quarter.
  • Across five years, Inventory topped out at $4.0 million in Q4 2025 and bottomed at $918406.1 in Q4 2024.
  • The 3-year median for Inventory is $1.7 million (2023), against an average of $2.1 million.
  • The widest annual swing landed in 2024, when Inventory slumped 59.1%; it then surged 339.34% in 2025.
  • A 3-year view of Inventory shows it stood at $2.2 million in 2023, then plunged by 59.1% to $918406.1 in 2024, then soared by 339.34% to $4.0 million in 2025.
  • The last three Inventory figures came in at $4.0 million (Q4 2025), $1.2 million (Q2 2025), and $918406.1 (Q4 2024), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inventory (Qtr)
1 Quantum Biopharma 1,638,563.89 Bn 1,638,563.89 Bn - -
2 Alterity Therapeutics 767,934.24 Bn 767,934.20 Bn - -
3 Legend Biotech 2,937.00 Bn 2,936.10 Bn 242.10 Mn 32.00 Mn
4 Nanobiotix 2,282.79 Bn 2,282.72 Bn - -
5 Akari Therapeutics 2,169.69 Bn 2,169.69 Bn - -
6 Vertex Pharmaceuticals 110.41 Bn 103.16 Bn 2.59 Bn 1.77 Bn
7 Regeneron Pharmaceuticals 66.44 Bn 57.69 Bn 3.31 Bn 3.10 Bn
8 Evaxion A 65.44 Bn 65.42 Bn - -
9 Alnylam Pharmaceuticals 39.53 Bn 36.52 Bn 959.66 Mn 84.03 Mn
10 Ascentage Pharma Group International 1.11 Bn 937.28 Mn - 4.03 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 4.03 Mn
Jun 30, 2025 1.20 Mn
Dec 31, 2024 918,406.10
Dec 31, 2023 2.25 Mn